ArticleJMIR cancer2025
Leveraging Digital Twins for Stratification of Patients with Breast Cancer and Treatment Optimization in Geriatric Oncology: Multivariate Clustering Analysis.
Article in JMIR cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From mechanistic models to artificial intelligence: exploring the potential of digital twins in geriatric oncology.Frontiers in artificial intelligence · 2026Article
- Digital twins in healthcare: a comprehensive review and future directions.Frontiers in digital health · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Defining optimal adjuvant therapeutic strategies for older adult patients with breast cancer remains a challenge, given that this population is often overlooked and underserved in clinical research and decision-making tools. objectives: This study aimed to develop a prognostic and treatment guidance tool tailored to older adult patients using artificial intelligence (AI) and a combination of clinical and biological features. Methods: A retrospective analysis was conducted on data from women aged 70+ years with HER2-negative early-stage breast cancer treated at the French Léon Bérard Cancer Center between 1997 and 2016. Manifold learning and machine learning algorithms were applied to uncover complex data relationships and develop predictive models. Predictors included age, BMI, comorbidities, hemoglobin levels, lymphocyte counts, hormone receptor status, Scarff-Bloom-Richardson grade, tumor size, and lymph node involvement. The dimension reduction technique PaCMAP was used to map patient profiles into a 3D space, allowing comparison with similar cases to estimate prognoses and potential treatment benefits. Results: Out of 1229 initial patients, 793 were included after data refinement. The selected predictors demonstrated high predictive efficacy for 5-year mortality, with mean area under the curve scores of 0.81 for Random Forest Classification and 0.76 for Support Vector Classifier. The tool categorized patients into prognostic clusters and enabled the estimation of treatment outcomes, such as chemotherapy benefits. Unlike traditional models that focus on isolated factors, this AI-based approach integrates multiple clinical and biological features to generate a comprehensive biomedical profile. Conclusions: This study introduces a novel AI-driven prognostic tool for older adult patients with breast cancer, enhancing treatment guidance by leveraging advanced machine learning techniques. The model provides a more nuanced understanding of disease dynamics and therapeutic strategies, emphasizing the importance of personalized oncology care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.